Results 111 to 120 of about 22,815 (201)

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. [PDF]

, 2008
PURPOSE: To determine the incidence of and the risk factors for the development of retinal pigment epithelial (RPE) tears after intravitreal bevacizumab (Avastin) injection for the treatment of exudative age-related macular degeneration (AMD). METHODS: A
Brod, Roy, Fischer, David, Garg, Sunir, Kim, David, Lane, R Gary, Maguire, Joseph   +5 more
core   +2 more sources

The impact of systemic long‐term medications for the development of age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä, Reijo Sund, Toni Rikkonen, Kai Kaarniranta   +3 more
wiley   +1 more source

Comparison of Incidence And Prognosis of Acute Endophthalmitis after Cataract Surgery And Intravitreal Avastin Injection

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2021
BACKGROUND AND OBJECTIVE: Acute endophthalmitis is one of the most dangerous complications after eye surgeries. Knowing the severity of this complication is critical for treatment policy in ophthalmology departments.
A Eftekhari Milani, N Hassanpoor, H Farshkaran, V Manouchehri, MR Niyousha   +4 more
doaj  

Anti-VEGF for the Management of Diabetic Macular Edema [PDF]

, 2014
Diabetic retinopathy (DR) is an important cause of vision loss around the world, being the leading cause in the population between 20 and 60 years old. Among patients with DR, diabetic macular edema (DME) is the most frequent cause of vision impairment ...
Badaro, Emmerson, Falabella, Paulo, Farah, Michel Eid, Koss, Michael, Maia, Mauricio, Stefanini, Francisco Rosa   +5 more
core   +2 more sources

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies, Yohei Hashimoto, Rahman Nazari, Jennifer Arnold, Beibei Wang, Richard Barry, Ross Ferrier, Justin Game, Daniel Barthelmes   +8 more
wiley   +1 more source

Prognostic Factors in Patients With Submacular Haemorrhage Complicating Age‐Related Macular Degeneration: A Post Hoc Analysis of the STAR Study

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To investigate prognostic factors of recent submacular haemorrhage (SMH) complicating neovascular age‐related macular degeneration (nAMD) treated with surgery or pneumatic displacement combined with intravitreal injection of anti‐vascular endothelial growth factor.
Pierre‐Henry Gabrielle, Petra Eid, Ludwig Serge Aho, Laurent Kodjikian, Eric Souied, Joel Uzzan, Jean Baptiste Conart, Marie‐Noëlle Delyfer, Catherine Creuzot‐Garcher   +8 more
wiley   +1 more source

Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye

Journal of Current Ophthalmology, 2019
Purpose: To evaluate the effects of anti-vascular endothelial growth factors (anti-VEGF) on the vessels of the non-treated eyes following intravitreal injections.
Mohammadreza Peyman, Alireza Peyman, Van C. Lansingh, Amirhossein Orandi, Visvaraja Subrayan   +4 more
doaj   +1 more source

Viral Vector-based Improvement of Optic Nerve Regeneration: Characterization of Individual Axons\u27 Growth Patterns and Synaptogenesis in a Visual Target [PDF]

, 2015
Lack of axon growth ability in the central nervous system poses a major barrier to achieving functional connectivity after injury. Thus, a non-transgenic regenerative approach to reinnervating targets has important implications in clinical and research ...
Blackmore, Murray G., Luo, Xueting, Salgueiro, Yadira, Yungher, Benjamin J.   +3 more
core   +1 more source

Intraocular Metastasis: Differential Diagnosis and Management

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Intraocular metastases represent the most common type of malignant intraocular tumour in adults. These commonly affect the choroid but can also involve the iris, ciliary body, retina, vitreous, optic disc or lens. Breast and lung cancer are the most common origins of intraocular metastases.
Genovefa Μachairoudia, Dimitrios Kazantzis, Guy S. Negretti, Mandeep S. Sagoo   +3 more
wiley   +1 more source